Immunology and Microbiology
Immunogenicity
100%
Serotype
90%
Pneumococcal Vaccine
58%
Human Respiratory Syncytial Virus
39%
Immune Response
36%
Conjugate Vaccine
32%
Otitis Media
31%
Pertussis Vaccine
30%
Adolescence
30%
Nontypeable Haemophilus Influenzae
28%
Whole Cell
25%
Infancy
24%
Titer
23%
Tetanus Vaccine
19%
Influenza
19%
Influenza Vaccine
18%
COVID-19
18%
Booster Dose
18%
Neisseria meningitidis
18%
Immunity
17%
Immunological Memory
16%
Antibodies
16%
Blood Plasma
16%
Infectious Agent
15%
Cytokine
15%
Normal Human
15%
Immunoglobulin E
15%
Antibody Titer
14%
Pneumococcal Polysaccharide Vaccine
14%
Haemophilus influenzae
13%
Antibody Response
13%
Staphylococcus Aureus
13%
Prevalence
12%
Neutrophil
12%
Allergen
11%
Virus
11%
Food Allergy
11%
Immunoglobulin G
10%
Immunoassay
10%
Staphylococcus Epidermidis
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Cytokine Response
9%
Interleukin 13
9%
Upper Respiratory Tract
9%
Middle Ear
8%
Interferon Type I
8%
Chickenpox
8%
Interleukin 10
8%
Biofilm
8%
Haemophilus
8%
Medicine and Dentistry
Diseases
56%
Serotype
47%
Adolescence
33%
Randomized Controlled Trial
31%
Cohort Analysis
30%
Immunogenicity
27%
Pneumococcus Vaccine
27%
Pertussis
26%
Otitis Media
26%
Influenza Vaccine
26%
Human Respiratory Syncytial Virus
26%
Adverse Event
22%
COVID-19
22%
Toddlers
21%
Infection
21%
Prevalence
21%
Virus
21%
Meningococcal Disease
17%
Pediatrics
16%
Pertussis Vaccine
15%
Respiratory Tract Infection
15%
Placebo
14%
Odds Ratio
14%
Sepsis
13%
Immune Response
13%
Case-Control Study
13%
Neisseria meningitidis
13%
Influenza Vaccination
12%
Pathogen
12%
Gene Linkage
12%
Neonatal Infant
12%
Acute Otitis Media
12%
Middle Ear
11%
Respiratory Disease
11%
Observational Study
10%
Conjugate Vaccine
10%
Severe Acute Respiratory Syndrome Coronavirus 2
10%
Febrile Seizure
10%
Infancy
10%
Secretory Otitis Media
9%
Whole Cell
9%
Cross Sectional Study
8%
Community-Acquired Pneumonia
8%
Pneumococcus Polysaccharide
8%
Health Service
8%
Systematic Review
8%
Booster Dose
8%
COVID-19 Vaccine
7%
Polysaccharide Vaccine
7%
Cohort Effect
7%
Pharmacology, Toxicology and Pharmaceutical Science
Immunogenicity
66%
Diseases
43%
Pertussis
36%
Adverse Event
32%
Pneumococcus Vaccine
29%
Human Respiratory Syncytial Virus
27%
Placebo
25%
Live Attenuated Influenza Vaccine
25%
Randomized Controlled Trial
23%
Pertussis Vaccine
19%
SARS Coronavirus
17%
Cohort Study
13%
Febrile Convulsion
13%
Sepsis
12%
Normal Human
12%
Clinical Trial
11%
Antibiotics
11%
COVID-19 Vaccine
10%
Tolerability
10%
Chronic Suppurative Otitis Media
10%
Conjugate Vaccine
9%
Coronavirinae
9%
Respiratory Tract Disease
8%
Infection
8%
Prematurity
8%
Chickenpox Vaccine
8%
Tetanus
7%
Observational Study
7%
Diphtheria
7%
Polysaccharide Vaccine
7%
Immunoglobulin G
7%
Pneumococcus Polysaccharide
6%
Immunoglobulin E
6%
Anaphylaxis
6%
Chickenpox
6%
Neutralizing Antibody
6%
Vaccine Efficacy
5%
Infectious Agent
5%
Influenza Vaccine
5%
Syndrome
5%
Immunoassay
5%
Comorbidity
5%
Haemophilus Influenzae Type B
5%
Diphtheria Pertussis Tetanus Vaccine
5%
Prevalence
5%
Prospective Cohort Study
5%
Binding Protein
5%
Influenza A Virus (H5N1)
5%
Hepatitis B Virus
5%
Palivizumab
5%